Emisphere has two Phase III product candidates based on the compound salmon calcitonin in collaboration with Novartis Pharma AG and its development partner, Nordic Bioscience. One product is being tested for the prevention of osteoporosis and the other product for the prevention of osteoarthritis. The osteoarthritis product has the potential to be the first disease-modifying drug that could halt progression of the illness, rather than treating symptoms. Both product candidates use Emisphere's eligen(R) delivery technology to provide salmon calcitonin as a convenient oral medication. There will be over 5000 patients enrolled in Phase III trials for these products by mid-year.
Emisphere has two product candidates in Phase II, oral heparin and oral
insulin, about which the Company is conducting an ongoing evaluation of
strategic options. The Company will provide updates as more information
Emisphere has six product candidates in Phase I:
-- Genta Incorporated began a Phase I clinical study of oral gallium in
the third quarter of 2007;
-- A research partner has conducted Phase I studies of acyclovir; we and
our partner are reviewing the data from that program to determine
-- Satiety and oral glucose challenge studies for both GLP-1 and PYY were
started in humans with data expected during the second quarter of this
-- Parathyroid hormone and human growth hormone are in development in
collaboration with Novartis Pharma AG
Emisphere conducts a variety of preclinical research and development programs, both in collaboration with pharmaceutical and biotechnology companies and independently. These programs are subject to ongoing review to determine whether the projects should continue and whether the independent projects are appropriate for further development or licensing.
|SOURCE Emisphere Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved